NCT03361306View on ClinicalTrials.gov

LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 9, 2018

Primary Completion Date

June 4, 2021

Study Completion Date

February 14, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

Elotuzumab

Experimental

Trial Locations (1)

28204

Levine Cancer Institute, Charlotte

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Atrium Health Levine Cancer Institute

OTHER

lead

Wake Forest University Health Sciences

OTHER

NCT03361306 - LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter